Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
Summary
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
Description
In this study, the researchers want to probe the role of the 5-HT2A receptor in mediating the subjective effects of psilocybin. While previous studies have shown that blockage of the 5-HT2A receptor reduces the psychedelic experience in humans, an animal study revealed that blockage of the 5- HT2A receptor abolished the psychedelic effects without affecting the antidepressant response. This suggests that the pathway responsible for the antidepressant response is dissociated from the psychedelic experience pathway, which is mediated by 5-HT2A signaling.
Eligibility
- Age range
- 21–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 21-80 years, any gender * Current primary diagnosis of Unipolar Major Depressive Disorder (MDD) without psychotic features using DSM-5 criteria * 24-item Hamilton Rating Scale for Depression (HRSD) ≥16 * Current diagnosis of Major Depressive Episode (MDE) * Capable of providing informed consent and complying with study procedures * Currently using or agreeing to use a highly effective contraception, if person of childbearing potential (such as condoms, IUD, or oral contraceptive), for duration of the study. Male participants agree to use highly effective contraceptio…
Interventions
- DrugPsilocybin
Psilocybin, 25mg, given once orally.
- DrugPimavanserin
Pimavanserin, 34mg, given once orally
- DrugPlacebo
Matching placebo.
Location
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York